Lung Cancer Clinical Trial
— EVIDENSOfficial title:
EVIDENS: Lung Cancer Patients Treated With Nivolumab: A Longitudinal, Prospective, Observational, Multicentric Study
NCT number | NCT03382496 |
Other study ID # | CA209-417 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 1, 2016 |
Est. completion date | December 23, 2020 |
Verified date | May 2022 |
Source | Bristol-Myers Squibb |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will describe the characteristics of patients initiating nivolumab treatment for lung cancer and their outcomes over 3 years in France
Status | Completed |
Enrollment | 1462 |
Est. completion date | December 23, 2020 |
Est. primary completion date | December 23, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male or female: 18 age at the time of nivolumab initiation - Pathologically confirmed diagnosis of lung cancer - Patient initiating nivolumab :therapeutic decision to initiate nivolumab must be taken by the physician prior to enrolling a patient in the study Exclusion Criteria: -Patient taking part in an interventional study for lung cancer treatment for which nivolumab is 1 of the investigational drugs Other protocol defined inclusion or exclusion criteria could apply |
Country | Name | City | State |
---|---|---|---|
France | Local Institution | Fontaine Les Dijon |
Lead Sponsor | Collaborator |
---|---|
Bristol-Myers Squibb |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Distribution of gender | At baseline | ||
Primary | Distribution of age | At baseline | ||
Primary | Distribution of line of therapy at nivolumab initiation | At baseline | ||
Primary | Distribution of ECOG PS | Eastern Cooperative Oncology Group Performance Status (ECOG PS) A scale used to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis | At baseline | |
Primary | Distribution of patients working status at nivolumab initiation | At baseline | ||
Primary | QoL (EQ-5D) at nivolumab initiation | Quality of Life (QoL) as assessed by European Quality of Life-5 Dimensions (EQ-5D) EQ-5D: the descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each with 3 levels (eg, no problems, moderate problems, extreme problems) | At baseline | |
Primary | Median time from initial diagnosis to nivolumab initiation | Median time from initial diagnosis to nivolumab initiation (derived from date of initial diagnosis and date of first dose of nivolumab, assumed to be the date of D0 visit). Any lung cancer declaring more than 5 years after another cancer is defined as an initial diagnosis of lung cancer | At baseline | |
Primary | Number of patients exposed to other lung cancer treatments | At baseline | ||
Primary | Distribution of current smokers, former smokers, and non-smokers at initial diagnosis | At baseline | ||
Primary | Distribution of cancer stage at initial diagnosis and at nivolumab initiation | At baseline | ||
Primary | Distribution of Lung cancer histology at initial diagnosis | At baseline | ||
Primary | Number of patients with untreated brain metastasis at nivolumab initiation | At baseline | ||
Primary | Number of patients with treated brain metastasis at nivolumab initiation | At baseline | ||
Primary | Number of patients with PD-L1 expression at nivolumab initiation | PD-LI (Programmed death-ligand 1) | At baseline | |
Primary | Number of patients with mutations at nivolumab initiation | At baseline | ||
Primary | Distribution of concomitant diseases at nivolumab initiation | At baseline | ||
Primary | Number of patients with corticosteroids treatment at nivolumab initiation | At baseline | ||
Primary | (OS) Overall Survival | Time from index date (treatment with nivolumab) until date of death due to any cause | Up to 3 years | |
Secondary | Overall Survival after initiation of nivolumab | Up to 2 years | ||
Secondary | Distribution of nivolumab adverse drug reaction | At 3 years after nivolumab initiation | ||
Secondary | Progression Free Survival (PFS) | PFS measured by time since index date (initial treatment with nivolumab) to either the first disease progression date or last known tumor assessment date, or death due to any cause, whichever occurs first as assessed by RECIST 1.1 | Up to 3 years after nivolumab initiation | |
Secondary | Objective Response Rate (ORR) | ORR is measured by the sum of partial responses plus complete responses as assessed by (RECIST 1.1) Response Evaluation Criteria In Solid Tumors | Up to 3 years after nivolumab initiation | |
Secondary | Quality of Life (QoL) | Baseline to 3 years after nivolumab initiation | ||
Secondary | Distribution of patient management treatment patterns | Baseline to 3 years | ||
Secondary | Mean weight change in kilogram from baseline | Baseline up to 3 years | ||
Secondary | Mean ECOG PS change from baseline | Baseline up to 3 years | ||
Secondary | Distribution of patients with new metastasis | Up to 3 years | ||
Secondary | Distribution of patients with progression of pre-existing sites | Up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|